Skip to main navigation Skip to search Skip to main content

A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal

  • Pamela R. Schroeder
  • , Bryan R. Haugen
  • , Furio Pacini
  • , Christoph Reiners
  • , Martin Schlumberger
  • , Steven I. Sherman
  • , David S. Cooper
  • , Kathryn G. Schuff
  • , Lewis E. Braverman
  • , Monica C. Skarulis
  • , Terry F. Davies
  • , Ernest L. Mazzaferri
  • , Gilbert H. Daniels
  • , Douglas S. Ross
  • , Markus Luster
  • , Mary H. Samuels
  • , Bruce D. Weintraub
  • , E. Chester Ridgway
  • , Paul W. Ladenson

Research output: Contribution to journalArticlepeer-review

Abstract

Context: Thyroid carcinoma requires lifelong monitoring with serum thyroglobulin, radioactive iodine whole body scanning, and other imaging modalities. Levothyroxine (L-T4) withdrawal for thyroglobulin measurement and whole body scanning increases these tests' sensitivities but causes hypothyroidism. Recombinant human TSH (rhTSH) enables testing without L-T4 withdrawal. Objective: Our objective was to examine the impact of short-term hypothyroidism on the health-related quality of life (HRQOL) of patients after rhTSH vs. L-T4 withdrawal. Design, Setting, and Patients: In this multicenter study, the SF-36 Health Survey was administered to 228 patients at three time points: on L-T4, after rhTSH, and after L-T4 withdrawal. Interventions: Interventions included administration of rhTSH on L-T4 and withdrawal from thyroid hormone. Main Outcome Measures: Mean SF-36 scores were compared during the two interventions and with the U.S. general population and patients with heart failure, depression, and migraine headache. Results: Patients had SF-36 scores at or above the norm for the general U.S. population in six of eight domains at baseline on L-T 4 and in seven of eight domains after rhTSH. Patients' scores declined significantly in all eight domains after L-T4 withdrawal when compared with the other two periods (P < 0.0001). Patients' HRQOL scores while on L-T4 and after rhTSH were at or above those for patients with heart failure, depression, and migraine in all eight domains. After L-T4 withdrawal, patients' HRQOL scores were significantly below congestive heart failure, depression, and migraine headache norms in six, three, and six of the eight domains, respectively. Conclusions: Short-term hypothyroidism after L-T4 withdrawal is associated with a significant decline in quality of life that is abrogated by rhTSH use.

Original languageEnglish (US)
Pages (from-to)878-884
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume91
Issue number3
DOIs
StatePublished - Mar 2006

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint

Dive into the research topics of 'A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal'. Together they form a unique fingerprint.

Cite this